These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 14609623)

  • 1. Cardiovascular effects of tadalafil in patients on common antihypertensive therapies.
    Kloner RA; Mitchell M; Emmick JT
    Am J Cardiol; 2003 Nov; 92(9A):47M-57M. PubMed ID: 14609623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular effects of tadalafil.
    Kloner RA; Mitchell M; Emmick JT
    Am J Cardiol; 2003 Nov; 92(9A):37M-46M. PubMed ID: 14609622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roundtable discussion: tadalafil study group.
    Kloner RA; Brindis RG; Cheitlin MD; Kuritzky L; Miller TA; Padma-Nathan H; Rosen RC
    Am J Cardiol; 2003 Nov; 92(9A):58M-65M. PubMed ID: 14609624
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and tolerability of tadalafil, a novel phosphodiesterase 5 inhibitor, in treatment of erectile dysfunction.
    Padma-Nathan H
    Am J Cardiol; 2003 Nov; 92(9A):19M-25M. PubMed ID: 14609620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions.
    Kloner RA
    Am J Cardiol; 2005 Dec; 96(12B):42M-46M. PubMed ID: 16387566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overall cardiovascular profile of sildenafil citrate.
    Zusman RM; Morales A; Glasser DB; Osterloh IH
    Am J Cardiol; 1999 Mar; 83(5A):35C-44C. PubMed ID: 10078541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of tadalafil in men with erectile dysfunction naïve to phosphodiesterase 5 inhibitor therapy compared with prior responders to sildenafil citrate.
    Broderick GA; Donatucci CF; Hatzichristou D; Torres LO; Valiquette L; Zhao Y; Loughney K; Sides GD; Ahuja S
    J Sex Med; 2006 Jul; 3(4):668-675. PubMed ID: 16839323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sexual function in hypertensive patients receiving treatment.
    Reffelmann T; Kloner RA
    Vasc Health Risk Manag; 2006; 2(4):447-55. PubMed ID: 17323599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tadalafil improved erectile function at twenty-four and thirty-six hours after dosing in men with erectile dysfunction: US trial.
    Young JM; Feldman RA; Auerbach SM; Kaufman JM; Garcia CS; Shen W; Murphy AM; Beasley CM; Hague JA; Ahuja S
    J Androl; 2005; 26(3):310-8. PubMed ID: 15866997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of integrated clinical safety data of tadalafil in patients receiving concomitant antihypertensive medications.
    Kloner RA; Kostis JB; McGraw TP; Qiu C; Gupta A
    J Clin Hypertens (Greenwich); 2022 Feb; 24(2):167-178. PubMed ID: 35099113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tadalafil.
    Curran M; Keating G
    Drugs; 2003; 63(20):2203-12; discussion 2213-4. PubMed ID: 14498756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of tadalafil in a Western European population of men with erectile dysfunction.
    Eardley I; Gentile V; Austoni E; Hackett G; Lembo D; Wang C; Beardsworth A
    BJU Int; 2004 Oct; 94(6):871-7. PubMed ID: 15476525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective Observational Real-World Outcome Study to Evaluate Safety Among Patients With Erectile Dysfunction (ED) With Co-Possession of Tadalafil and Anti-Hypertensive Medications (anti-HTN).
    Nunes AP; Seeger JD; Stewart A; Gupta A; McGraw T
    J Sex Med; 2022 Jan; 19(1):74-82. PubMed ID: 34872842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular effects of phosphodiesterase 5 inhibitors.
    Reffelmann T; Kloner RA
    Curr Pharm Des; 2006; 12(27):3485-94. PubMed ID: 17017941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase.
    Kukreja RC
    Br J Pharmacol; 2007 Mar; 150(5):538-40. PubMed ID: 17245364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of phosphodiesterase 5 inhibition in erectile dysfunction.
    Rosen RC; Kostis JB
    Am J Cardiol; 2003 Nov; 92(9A):9M-18M. PubMed ID: 14609619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects.
    Giuliano F; Kaplan SA; Cabanis MJ; Astruc B
    Urology; 2006 Jun; 67(6):1199-204. PubMed ID: 16765179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of oral tadalafil in the treatment of men in Canada with erectile dysfunction: a randomized, double-blind, parallel, placebo-controlled clinical trial.
    Carrier S; Brock GB; Pommerville PJ; Shin J; Anglin G; Whitaker S; Beasley CM
    J Sex Med; 2005 Sep; 2(5):685-98. PubMed ID: 16422827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of tadalafil in United States and Puerto Rican men with erectile dysfunction.
    Seftel AD; Wilson SK; Knapp PM; Shin J; Wang WC; Ahuja S
    J Urol; 2004 Aug; 172(2):652-7. PubMed ID: 15247754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
    Ravipati G; McClung JA; Aronow WS; Peterson SJ; Frishman WH
    Cardiol Rev; 2007; 15(2):76-86. PubMed ID: 17303994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.